Redmile Group, LLC's Net Worth

$47.8 Million

Who is Redmile Group, LLC?

Redmile Group, LLC has an estimated net worth of $47.8 Million. This is based on reported shares across multiple companies, which include ALDER BIOPHARMACEUTICALS INC, XERIS PHARMACEUTICALS INC, RayzeBio, Inc., Allakos Inc., Science 37 Holdings, Inc., PLIANT THERAPEUTICS, INC., Stoke Therapeutics, Inc., Absci Corp, Adagio Therapeutics, Inc., Gritstone Oncology, Inc., Entrada Therapeutics, Inc., Repare Therapeutics Inc., Allovir, Inc., IGM Biosciences, Inc., Verve Therapeutics, Inc., Nurix Therapeutics, Inc., Akero Therapeutics, Inc., Replimune Group, Inc., AMICUS THERAPEUTICS INC, FATE THERAPEUTICS INC, Kymera Therapeutics, Inc., Beam Therapeutics Inc., Augmedix, Inc., Neoleukin Therapeutics, Inc., Syros Pharmaceuticals, Inc., Atreca, Inc., VAPOTHERM INC, Shattuck Labs, Inc., TCR2 THERAPEUTICS INC., HOOKIPA Pharma Inc., Cabaletta Bio, Inc., Annexon, Inc., MedAvail Holdings, Inc., Aprea Therapeutics, Inc., ARRAY BIOPHARMA INC, Zymeworks Inc., and ADC Therapeutics SA.

SEC CIK

Redmile Group, LLC's CIK is 0001425738

Past Insider Trading and Trends

2024 was Redmile Group, LLC's most active year for acquiring shares with 20 total transactions. Redmile Group, LLC's most active month to acquire stocks was the month of December. 2016 was Redmile Group, LLC's most active year for disposing of shares, totalling 5 transactions. Redmile Group, LLC's most active month to dispose stocks was the month of June. 2024 saw Redmile Group, LLC paying a total of $30,511,754.97 for 8,297,647 shares, this is the most they've acquired in one year. In 2023 Redmile Group, LLC cashed out on 5,000,000 shares for a total of $15,000,000.00, their largest year based on trade value.